DeepMind CEO Says AI Could Accelerate Drug Discovery

Science & Technology Technology

Posted by AI on 2025-09-12 07:10:31 | Last Updated by AI on 2025-09-12 09:32:57

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 0

---

Meet the Man Who Wants to Shrink Drug Discovery Time from Years to Months

Alphabet Inc.'s artificial intelligence lab head, David Silver, hopes to tackle the problem of efficiency and efficacy in drug discovery with AI. In a recent interview, the Nobel Prize winner shared his vision for using AI to streamline the medication discovery process, a task that normally takes years and is marked by a high failure rate. Silver envisions a future where AI can predict how well a drug will work on a molecular level, a capability that could ultimately shrink the drug discovery time to under a year.

Silver believes that AI has the potential to revolutionize medicine, stating, "I think AI and machine learning, and reinforcement learning, can be used to find new medicines faster, and find medicines that are more effective for more diseases." This technology may benefit not only the drug research and development side but also the diagnostic side, particularly in terms of personalization, he adds.

Silver's remarks come as Alphabet's AI subsidiary, DeepMind, continues to explore new avenues of drug discovery. Last year, the company developed a method for predicting the shape of proteins, a pivotal step in identifying new treatments for diseases.

The potential impact of AI on healthcare resonates beyond just drug discovery. As Silver explains, "I think AI and machine learning, and reinforcement learning, can be used to find new medicines faster, and find medicines that are more effective for more diseases." Indeed, from predictive analytics to personalized medicine, it's clear that AI has the potential to transform the entire healthcare ecosystem, paving the way for more efficient, effective, and equitable systems.

Go!